Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.

Eur Heart J Cardiovasc Pharmacother · 2019 · PMC6749839 · PMID 31218354

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients who qualified on just one of the EMA requirements, the difference between ticagrelor and placebo did not reach statistical significance although the trend towards the benefit is still present.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.